SCHEMBL561809

SCHEMBL561809

NCCCNCCCNCCCNCCCN

nearest known ligand 0.92

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.86
CA6 P23280 5/20 0.86
CA7 P43166 5/20 0.86
CA9 Q16790 5/20 0.86
CA14 Q9ULX7 5/20 0.86
CA5B Q9Y2D0 5/20 0.86
CA2 P00918 4/20 0.86
CA4 P22748 4/20 0.86
CA5A P35218 4/20 0.86
ALOX15 P16050 3/20 0.86
CASP2 P42575 2/20 0.86
F13A1 P00488 2/20 0.86
CYP1A2 P05177 2/20 0.86
THPO P40225 2/20 0.86
MEN1 O00255 2/20 0.86
RECQL P46063 2/20 0.86
KMT2A Q03164 2/20 0.86
CYP2C19 P33261 1/20 0.86
HSD17B10 Q99714 1/20 0.86
CA3 P07451 3/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3159043 1.00 CA12 (0.86) CA12CA6CA7CA9CA14
SCHEMBL868754 1.00 CA12 (0.86) CA12CA6CA7CA9CA14
SCHEMBL869691 1.00 CA12 (0.86) CA12CA6CA7CA9CA14
Thermine SCHEMBL181589 1.00 CA12 (0.86) CA12CA6CA7CA9CA14
SCHEMBL869672 1.00 CA12 (0.86) CA12CA6CA7CA9CA14
SCHEMBL869496 1.00 CA12 (0.86) CA12CA6CA7CA9CA14
SCHEMBL870789 1.00 CA12 (0.86) CA12CA6CA7CA9CA14
SCHEMBL869794 1.00 CA12 (0.86) CA12CA6CA7CA9CA14
Thermine SCHEMBL8837088 0.96 CASP2 (0.93) CA12CA6CA7CA9CA14
SCHEMBL9718728 0.96 CASP2 (0.93) CA12CA6CA7CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 980 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12639248-B2 Handling node policies in a firmware framework DELL PRODUCTS L.P. (US) 2026-05-26 US claimed
US-12624503-B2 Composition for improving softness of tissue and/or towel products SOLENIS TECHNOLOGIES, L.P. (US) 2026-05-12 US claimed
EP-4731603-A1 LOW TEMPERATURE REACTIVE ARYL AZIDES SuSoS AG (CH) 2026-04-29 EP claimed
EP-4018465-B1 SUPERCAPACITORS COMPRISING PHOSPHONATE AND ARSONATE METAL ORGANIC FRAMEWORKS (MOFS) AS ACTIVE ELECTRODE MATERIALS UNIV BERLIN TECH (DE) 2025-12-17 EP claimed
CN-120199404-A Method, system and equipment for constructing automatic auditing rules of clinical immunodetection 首都医科大学附属北京妇产医院 2025-06-24 CN claimed
US-12325842-B2 Decontamination paste consisting of clays and microfibers and method for decontaminating a solid material using said paste Commissariat à l'énergie atomique et aux énergies alternatives (FR) 2025-06-10 US claimed
CN-120040780-A Method for regulating and controlling luminescence of triphenylamine metal-organic framework material based on mixed ligand strategy 浙江大学 2025-05-27 CN claimed
EP-4539968-A1 TREATED MICROPOROUS MEMBRANE PPG Industries Ohio Inc. (US) 2025-04-23 EP claimed
CN-119355253-B TPPA reaction unit 杭州市临安区第一人民医院(杭州市临安区第一人民医院医共体) 2025-04-11 CN claimed
WO-2025070707-A1 COMPOSITION CONTAINING DIAMINE AND/OR POLYAMINE FOR PREVENTING OR IMPROVING FRAILTY 東洋紡株式会社 2025-04-03 WO claimed
EP-1351972-A1 LIPIDS COMPRISING AN AMINOXY GROUP Mitsubishi Chemical Corporation (JP) 2003-10-15 EP claimed
WO-2003047549-A2 POST-COATED LIPOSOME/LIPOPLEX FOR TARGETED DRUG/GENE DELIVERY AND LIPID LINKED TO A DELIVERY, TARGETING OR STABILISING MOIETY MITSUBISHI CHEMICAL CORPORATION (JP) 2003-06-12 WO claimed
US-20020188023-A1 Compound IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) 2002-12-12 US claimed
WO-2002048170-A1 LIPIDS COMPRISING AN AMINOXY GROUP MITSUBISHI CHEMICAL CORPORATION (JP) 2002-06-20 WO claimed
WO-2002048380-A2 GLYCOSILATED CATIONIC LIPIDS FOR LIPOSOMES USED IN DRUG DELIVERY MITSUBISHI CHEMICAL CORPORATION (JP) 2002-06-20 WO claimed
US-6172261-B1 BIOSYNTHESIS USING CHAIN EXTENSION ORIDIGM CORPORATION 2001-01-09 US claimed
EP-1001927-A2 NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS ORIDIGM CORPORATION (US) 2000-05-24 EP claimed
EP-0918790-A1 POLYCATIONIC STEROL DERIVATIVES AS TRANSFECTION AGENTS IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE (GB) 1999-06-02 EP claimed
WO-1999003823-A2 NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS ORIDIGM CORPORATION (US) 1999-01-28 WO claimed
WO-1997045442-A1 POLYCATIONIC STEROL DERIVATIVES AS TRANSFECTION AGENTS IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE (GB) 1997-12-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12639248-B2 Handling node policies in a firmware framework INTS6, INTS9, ILK CA12 922/4885CA6 2562/4885CA7 3815/4885
US-12624503-B2 Composition for improving softness of tissue and/or towel products CUTA, TTPA, PHOSPHO1 CA12 2023/4885CA6 904/4885CA7 1941/4885
US-20020188023-A1 Compound CYP46A1, CYP11B2, NR1H3 CA12 654/4885CA6 873/4885CA7 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.